Details

Autor(en) / Beteiligte

• Aroda, Vanita R
• Rosenstock, Julio
• Terauchi, Yasuo
• Altuntas, Yuksel
• Lalic, Nebojsa M
• Morales Villegas, Enrique C
• Jeppesen, Ole K
• Christiansen, Erik
• Hertz, Christin L
• Haluzík, Martin

Titel

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

Ist Teil von

• Diabetes care, 2019-09, Vol.42 (9), p.1724-1732

Ort / Verlag

United States: American Diabetes Association

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• This trial compared the efficacy and safety of the first oral glucagon-like peptide 1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with type 2 diabetes managed by diet and exercise alone. Two estimands addressed two efficacy-related questions: a treatment policy estimand (regardless of trial product discontinuation or rescue medication use) and a trial product estimand (on trial product without rescue medication use) in all randomized patients. This was a 26-week, phase 3a, randomized, double-blind, placebo-controlled, parallel-group trial conducted in 93 sites in nine countries. Adults with type 2 diabetes insufficiently controlled with diet and exercise were randomized (1:1:1:1) to once-daily oral semaglutide 3 mg, 7 mg, 14 mg, or placebo. The primary end point was change from baseline to week 26 in HbA . The confirmatory secondary end point was change from baseline to week 26 in body weight. In the 703 patients randomized (mean age 55 years, 50.8% male, and mean baseline HbA 8.0% [64 mmol/mol]), oral semaglutide reduced HbA (placebo-adjusted treatment differences at week 26: treatment policy estimand, -0.6% [3 mg], -0.9% [7 mg], and -1.1% [14 mg]; trial product estimand, -0.7% [3 mg], -1.2% [7 mg], and -1.4% [14 mg]; < 0.001 for all) and body weight (treatment policy, -0.1 kg [3 mg], -0.9 kg [7 mg], and -2.3 kg [14 mg, < 0.001]; trial product, -0.2 kg [3 mg], -1.0 kg [7 mg, = 0.01], and -2.6 kg [14 mg, < 0.001]). Mild-to-moderate transient gastrointestinal events were the most common adverse events with oral semaglutide. Trial product discontinuations occurred in 2.3-7.4% with oral semaglutide and 2.2% with placebo. In patients with type 2 diabetes, oral semaglutide monotherapy demonstrated superior and clinically relevant improvements in HbA (all doses) and body weight loss (14 mg dose) versus placebo, with a safety profile consistent with other GLP-1 receptor agonists.